Zimbabwe has rejected a substantial US healthcare agreement valued at 367 million US dollars (£272m) spanning five years due to Washington's demand for sensitive data.
The decision came to light following a official document dated December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government representative later explained that the United States was demanding access to health data for scientific study and profit while was not willing to share the resulting advantages from future medical innovations.
"We are forced to start the challenging and unfortunate process of ending our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had provided more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged more dialogue to reach a deal suitable to all parties so the country's critical HIV programme can be sustained.
Broader Implications
This development comes after a similar case in Kenya, where a court halted a similar deal with the US following concerns were raised about the security of Kenyans' health data.
Since returning to office last year, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
The agency had administered aid for the American government, but Trump stated its spending was "inefficient" and his administration was pursuing direct bilateral deals to enhance openness and responsibility.
Based on statements, Sixteen African countries have so far agreed to these new agreements, representing over $18.3bn of fresh investment.
Details of the Rejected Deal
This assistance for Zimbabwe would have supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration might have yielded immense advantages for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy via US-supported programmes," Tremont commented.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"The proposal required Zimbabwe to share its genetic material and health information over an extended period, without any equivalent promise of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that provided information," Mangwana explained.
"Put simply, our country would provide the raw materials for scientific discovery without any assurance that the final treatments would be available to our citizens if a future health crisis arise."
National Interest and Global Health
Mangwana further noted that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were undermining frameworks already established through the international organization.
The spokesperson cited its Pandemic Benefit-Sharing framework created to manage potential global health emergencies.
"This framework is designed to ensure that when a nation provides its data, the resulting advantages – including medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to create them."
These objections regarding the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We are open to ongoing dialogue with our US partners on how subsequent co-operation might be designed in a way that honours the sovereignty and dignity of both nations."
Medical Community Response
Medical experts expressed it acknowledged the official position, but suggested that talks must proceed considering much of the country's HIV programmes relied on international support.
"In cases where technical issues exist, including those involving information security or agreement terms, these can often be addressed through detailed discussion and negotiated safeguards," it said.
This impasse emphasises the complex debate between receiving much-needed foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.